cll
No description yet: the sentence for this tag has not been written. 9 records carry it: 9 people.
Related tags
9 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Barbara Eichhorst Professor of Medicine and Head of the CLL Outpatient Clinic, University Hospital Cologne; Secretary, German CLL Study Group · Uniklinik Köln (CIO) Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients. | Chronic lymphocytic leukaemia | none | venetoclax, guidelines | ||
Constantine S. Tam Head of Lymphoma Service, Alfred Health; Professor of Haematology, Monash University · Alfred Health / Monash University Led the zanubrutinib SEQUOIA trial and the first ibrutinib-venetoclax study in mantle cell lymphoma. | Chronic lymphocytic leukaemia, Mantle cell lymphoma | none | btk, australia | ||
Jennifer A. Woyach Professor of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center · The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute Led Alliance A041202, which showed ibrutinib beats chemoimmunotherapy in older CLL patients, and discovered BTK C481S resistance. | Chronic lymphocytic leukaemia | none | btk, alliance | ||
Jennifer R. Brown Director, CLL Center, Dana-Farber Cancer Institute; Worthington and Margaret Collette Professor of Medicine, Harvard Medical School · Dana-Farber Brigham Cancer Center Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib. | Chronic lymphocytic leukaemia | none | btk, trialist | ||
John C. Byrd Chair, Department of Internal Medicine, University of Cincinnati College of Medicine · University of Cincinnati Cancer Center Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills. | Chronic lymphocytic leukaemia | none | btk, targeted-therapy | ||
John F. Seymour Director of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital · Peter MacCallum Cancer Centre Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL. | Chronic lymphocytic leukaemia | none | venetoclax, australia | ||
Kirsten Fischer Senior Physician and Study Coordinator, German CLL Study Group, University Hospital Cologne · Uniklinik Köln (CIO) Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment. | Chronic lymphocytic leukaemia | none | venetoclax, fixed-duration | ||
Peter Hillmen Emeritus Professor of Experimental Haematology, University of Leeds · Leeds Cancer Centre, St James's University Hospital Led FLAIR, the UK trial showing MRD-guided ibrutinib plus venetoclax outperforms chemoimmunotherapy in CLL. | Chronic lymphocytic leukaemia | none | mrd, uk | ||
William G. Wierda Professor and Section Chief of CLL, Department of Leukemia, MD Anderson Cancer Center · MD Anderson Cancer Center Led CAPTIVATE, which established fixed-duration ibrutinib plus venetoclax as a first-line option for CLL. | Chronic lymphocytic leukaemia | none | fixed-duration, guidelines |